Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154153 · ClinicalTrials.gov registry record · Phase 4
Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
A Phase 4 study of Rhinitis, Allergic, Perennial and/or Seasonal, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 8
- Study locations
NCT01154153 is a Phase 4 study of Rhinitis, Allergic, Perennial and/or Seasonal that has completed, run by Sanofi. The registered enrollment target is 140 participants. The trial reports 8 study locations across 8 states.
The verdict
NCT01154153, a Phase 4 study of Rhinitis, Allergic, Perennial and/or Seasonal, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 8
- Study locations
Study Summary
The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol AUC(0-24 hr) in children (\>=2 to \<12 years old) with allergic rhinitis (AR).
Conditions Studied
Interventions
- DRUG Placebo nasal spray
- DRUG Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)
- DRUG Claritin® Syrup
Study Locations (8)
California
- Investigational Site Number 840003 - Cypress
Georgia
- Investigational Site Number 840006 - Stockbridge
Massachusetts
- Investigational Site Number 840007 - North Dartmouth
Minnesota
- Investigational Site Number 840010 - Plymouth
Nebraska
- Investigational Site Number 840001 - Omaha
North Carolina
- Investigational Site Number 840008 - Raleigh
South Carolina
- Investigational Site Number 840002 - Spartanburg
Texas
- Investigational Site Number 840005 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154153
The ClinicalTrials.gov registry entry for NCT01154153 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rhinitis, Allergic, Perennial and/or Seasonal appearing as the primary indexed condition, and to 3 interventions - of which Placebo nasal spray is the first listed.
NCT01154153 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01154153 about?
NCT01154153 is a clinical study titled "Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis". The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol AUC(0-24 hr) in children (\>=2 to \<12 years old) with allergic rhinitis ...
What is the current status of trial NCT01154153?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2010-06. Estimated completion is 2010-10.
What conditions does trial NCT01154153 study?
This clinical trial studies the following conditions: Rhinitis, Allergic, Perennial and/or Seasonal.
What interventions are being tested in trial NCT01154153?
The interventions under investigation include: Placebo nasal spray (DRUG), Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) (DRUG), Claritin® Syrup (DRUG).
Who is sponsoring clinical trial NCT01154153?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01154153 being conducted?
This trial has 8 study locations across California, Georgia, Massachusetts, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.